Guggenheim Capital LLC Nurix Therapeutics, Inc. Transaction History
Guggenheim Capital LLC
- $13.9 Billion
- Q2 2024
Shares
3 transactions
Others Institutions Holding NRIX
# of Institutions
183Shares Held
66.4MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$153 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$99.3 Million6.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$89.6 Million2.73% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$87.2 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$81.4 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.06B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...